UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Neuroimaging and biomarker evidence of neurodegeneration in asthma

Rosenkranz, MA; Dean, DC; Bendlin, BB; Jarjour, NN; Esnault, S; Zetterberg, H; Heslegrave, A; ... Busse, WW; + view all (2022) Neuroimaging and biomarker evidence of neurodegeneration in asthma. Journal of Allergy and Clinical Immunology , 149 (2) 589-598.e6. 10.1016/j.jaci.2021.09.010. Green open access

[thumbnail of 1-s2.0-S0091674921013968-main.pdf]
Preview
Text
1-s2.0-S0091674921013968-main.pdf - Accepted Version

Download (3MB) | Preview

Abstract

Background: Epidemiological studies have shown that Alzheimer’s disease and related dementias (ADRD) are seen more frequently with asthma, especially with greater asthma severity or exacerbation frequency. // Objective: To examine the changes in brain structure that may underlie this phenomenon, we examined diffusion-weighted magnetic resonance imaging (dMRI) and blood-based biomarkers of AD (p-Tau181), neurodegeneration (NfL) and glial activation (GFAP). // Methods: dMRI data were obtained in 111 individuals with asthma, ranging in disease severity from mild to severe, and 135 healthy controls. Regression analyses were used to test the relationships between asthma severity and neuroimaging measures, as well as AD pathology, neurodegeneration and glial activation, indexed by plasma p-Tau181, NfL and GFAP respectively. Additional relationships were tested with cognitive function. // Results: Asthma participants had widespread and large magnitude differences in several dMRI metrics, which were indicative of neuroinflammation and neurodegeneration, and robustly associated with GFAP and to a lesser extent, with NfL. The AD biomarker p-Tau181 was only minimally associated with neuroimaging outcomes. Further, asthma severity was associated with deleterious changes in neuroimaging outcomes, which in turn, were associated with slower processing speed, a test of cognitive performance. // Conclusion: These data suggest that asthma, particularly when severe, is associated with characteristics of neuroinflammation and neurodegeneration and may be a potential risk factor for neural injury and cognitive dysfunction. The results suggest a need to determine how asthma may affect brain health and whether treatment directed toward characteristics of asthma associated with these risks can mitigate these effects.

Type: Article
Title: Neuroimaging and biomarker evidence of neurodegeneration in asthma
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.jaci.2021.09.010
Publisher version: https://doi.org/10.1016/j.jaci.2021.09.010
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: GFAP, NfL, asthma, dementia, diffusion-weighted imaging, inflammation, neurodegeneration
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10135758
Downloads since deposit
7,098Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item